2010 Jose Gaal.
van Nederveen FW, Gaal J, Favier J, Korpcrshoek E, Oldenburg RA, de Bruyn
EM, Sleddens HF, Derkx P, Riviere J, Dannenberg H, Petri BJ, Komminoth P, Pacak
K, Hop WC, Pollard PJ, Mannelli M, Bayley JP, Perren A, Niemann S, Verhofstad
AA, de Bruine AP, Maher ER, Tissier F, Meatchi T, Badoual C, Bertherat J, Amar L,
Alataki D, Van Marck E, Ferrau F, Francois J, de Herder WW, Peeters MP, van Linge
A, Lenders JW, Gimenez-Roqueplo AP, de Krijger RR, Dinjens WN. An
immunohistochemical procedure to detect patients with paraganglioma and
phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a
retrospective and prospective analysis. Lancet Oncol. 2009 Aug; 10(8):764-7 1.

 

2007: Tetsuo Kondo.
Kondo T, Zheng L, Liu W, Kurebayashi J, Asa SL, Ezzat S. Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression. Cancer Res. 2007 Jun 1;67(11):5461-70.

 

2006: Francien H van Nederveen
van Nederveen FH, Perren A, Dannenberg H, Petri BJ, Dinjens WN, Komminoth P, de Krijger RR. PTEN gene loss, but not mutation, in benign and malignant phaeochromocytomas. J Pathol. 2006 Jun;209(2):274-80.

 

2005: Martin Anlauf
Anlauf M, Wieben D, Perren A, Sipos B, Komminoth P, Raffel A, Kruse ML, Fottner C, Knoefel WT, Mönig H, Heitz PU, Klöppel G. Persistent hyperinsulinemic hypoglycemia in 15 adults with diffuse nesidioblastosis: diagnostic criteria, incidence, and characterization of beta-cell changes. Am J Surg Pathol. 2005 Apr;29(4):524-33.

 

2004: Hina A. Sheikh
Sheikh HA, Tometsko M, Niehouse L, Aldeeb D, Swalsky P, Finkelstein S, Barnes EL, Hunt JL. Molecular genotyping of medullary thyroid carcinoma can predict tumor recurrence. Am J Surg Pathol. 2004 Jan;28(1):101-6.